An Observational Study of RoActemra/Actemra in Patients With Moderate to Severe Rheumatoid Arthritis
Completed
- Conditions
- Rheumatoid Arthritis
- Registration Number
- NCT01375478
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This open-label, retrospective, observational study will evaluate the compliance to RoActemra/Actemra (tocilizumab) therapy in patients with moderate to severe rheumatoid arthritis. Six months data will be collected from patients records.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 197
Inclusion Criteria
- Adult patients, over 18 years of age
- Moderate to severe rheumatoid arthritis
- RoActemra/Actemra treatment must have been initiated 6 months prior to signing the informed consent form
Read More
Exclusion Criteria
- Patients with rheumatic autoimmune disease other than rheumatoid arthritis
- Patients who are not willing to sign the informed consent form
- Patients who participate in interventional trials during the period of this observational study
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of patients who remained under continued RoActemra/Actemra treatment 6 months
- Secondary Outcome Measures
Name Time Method Reasons for withdrawal 6 months Frequency of dose modification 6 months Reasons for dose modification 6 months Safety: Incidence of adverse events 6 months Frequency of withdrawal 6 months